Login to Your Account



Biogen IDEC Grows on Sales, Rises on BG-12 Data as Well

By Anette Breindl


Friday, April 22, 2011
Biogen Idec Inc. was up 15.2 percent Thursday on strong quarterly earnings and stout Phase III data for its multiple sclerosis (MS) drug BG-12.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription